Business Wire

The IKEA Foundation Identifies Highest Impact Interventions for Philanthropy to Reduce Emissions and Will Deploy an Additional €600m for Climate By 2025

Share

Shifting to alternative and plant-based proteins, supporting the market for electric 2&3 wheelers and providing targeted financial support for a fair and inclusive energy transition are among the highest impact opportunities global philanthropy can seize upon in the fight to reduce greenhouse gas (GHG) emissions, according to research commissioned by the IKEA Foundation.

The analysis, unveiled during the 2022 United Nations Climate Change Conference (COP27), was conducted in collaboration with the system change company, Systemiq and RMI, founded as the Rocky Mountain Institute, a nonprofit organisation working to accelerate the clean energy transition.

In 2021, the IKEA Foundation announced an additional €1 billion in funding for climate change programmes over a five-year period, with the strategic goal of quickly and significantly reducing global emissions. Of this commitment, €400 million has been earmarked for the Global Energy Alliance for People and Planet launched at COP26. The research conducted with Systemiq and RMI will inform how the IKEA Foundation deploys the remaining €600 million in climate funding.

The IKEA Foundation hopes publication of the research will drive greater investment in climate action efforts by the global philanthropic community, helping to keep alive the goal of limiting global warming to 1.5°C. Analysis by the ClimateWorks Foundation published in the run up to COP27 found that, despite a recent increase in climate philanthropy funding, still less than 2% of global philanthropic annual grants were dedicated to climate change mitigation in 2021.

Per Heggenes, CEO, IKEA Foundation, said: “We know that a rapid and sustained decrease in global emissions is required if the world is to meet its pledge of keeping global warming at or below 1.5°C. By sharing our research we hope to support and inspire other philanthropies, during this decisive decade for our planet, to step up their ambition to safeguard our environment.”

Jeremy Oppenheim, Founder of Systemiq, said: “Less than 2% of philanthropic capital goes to climate mitigation. This allocation needs to be scaled fast. But this is not just a volume game. It matters where and how philanthropy uses its capital. The methodology we developed with the IKEA Foundation and RMI could be the critical unlock that helps foundations prioritise the highest impact interventions to reduce emissions and deploy capital fast. The fact that the IKEA Foundation has chosen to open-source this analysis demonstrates their deep commitment to urgent climate action and belief in the catalytic role of a strategically coordinated philanthropic sector. “

Lena Hansen, Interim Chief Program & Strategy Officer, RMI said: “Collaboration is critical to implement solutions that set off catalytic tipping points and keep warming to 1.5C. RMI commends the IKEA Foundation for sharing this research with the world, and we hope that it helps spark radical collaboration to accelerate solutions to the climate crisis.”

The research considered five systems in which the consumption and production of GHG emissions needs to be transformed to limit global warming to 1.5°C: Energy & Power, Food & Land Use, Industry, Transport, and Buildings. It identified the key levers of change and high impact opportunity areas within these systems by considering: their potential to significantly reduce GHG emissions by 2030; the near-term viability of the technology required to meet the potential; their cost-effectiveness; and the ‘value add’ global philanthropy could provide in encouraging and maximising impact.

Some of the high impact opportunities identified are:

  • Providing targeted financial support to a fair and inclusive energy transition
  • Creating a market for minimizing upstream methane emissions
  • Creating the capacity for peatland protection/ restoration projects at government level
  • Stimulating a shift to alternative and plant-based protein
  • Creating the market & enabling environment for reducing methane emissions in agriculture
  • Invigorating efforts to strengthen value chains which can reduce losses
  • Supporting the market for electric 2 & 3 wheelers through operations and financing innovation
  • Space cooling in emerging economies Read the full research here

About the IKEA Foundation

The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families. In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.

About Systemiq

Systemiq, the system change company, was founded in 2016 to drive the achievement of the Sustainable Development Goals and the Paris Agreement, by transforming markets and business models in five key systems: nature and food, materials and circularity, energy, urban areas, and sustainable finance. A certified B Corp, Systemiq combines strategic advisory with high-impact, on-the-ground work, and partners with business, finance, policy- makers and civil society to deliver system change. Systemiq’s people are based in Brazil, France, Germany, Indonesia, the Netherlands and the UK. Find out more at www.systemiq.earth

About RMI

RMI is an independent nonprofit founded in 1982 that transforms global energy systems through market-driven solutions to align with a 1.5°C future and to secure a clean, prosperous, zero-carbon future for all. We work in the world’s most critical geographies and engage businesses, policymakers, communities, and NGOs to identify and scale energy system interventions that will cut greenhouse gas emissions by at least 50 percent by 2030. RMI has offices in: Basalt and Boulder, Colo.; New York City; Oakland, Calif.; Washington, D.C.; and Beijing.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hannah Moseley
+442037933800

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye